Viromed Medical AG Receives Approval for ViroCAP® med in Turkey and Announces Further Operational Progress

RELLINGEN, GERMANY - November 4, 2026 ( Uwe Perbandt, CEO of Viromed Medical AG: "The approval of ViroCAP® med in Turkey is a significant success for our international market development. Following the registration of ViroCAP® derma with the ÜTS (National Medical Device Tracking System) in the summer, we have already received approval for ViroCAP® med, which we had expected no earlier than February or March 2027. This marks another important milestone for the commercial launch of our ViroCAP® technology in a healthcare market that is strategically important for us." Viromed already has binding minimum orders for 7,000 ViroCAP® derma/med devices through the end of 2028 for the Turkish market. Deliveries will be made on the basis of the approval now granted. The required process for reimbursement by Turkish health insurers is already running in parallel. With this approval, Viromed continues its international expansion strategy and lays the foundation for the further development of the Turkish market. ViroCAP® med is designed for professional use by qualified medical personnel...